---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-010315"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:03:46.701424+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AgeX Therapeutics reports FY2022 net loss of $10.5M; cash only $0.7M, substantial doubt about going concern

## Summary
- Net loss of $10.5M ($0.28 per share) in FY2022 vs $8.7M ($0.23) in FY2021.
- Cash and restricted cash only $0.7M; owes Juvenescence $21.4M in loans.
- Substantial doubt about ability to continue as a going concern for next 12 months.
- Operating expenses fell to $7.0M from $8.2M; R&D decreased to $1.0M.

## SEC filing metadata
- accession: 0001493152-23-010315
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/0001493152-23-010315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-010315
- JSON: https://secwatch.observer/filing/0001493152-23-010315.json
- Plain text: https://secwatch.observer/filing/0001493152-23-010315.txt

## Key facts
- Earnings Releases
  Serina Therapeutics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue Total revenues for the fourth quarter of 2022 were $8,000 as compared with $27,000 for the fourth quarter of 2021. Total, net income Net loss attributable to AgeX for the year ended December 31, 2022 was $10.5 million, EPS ($0.28) per share (basic and diluted).
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Revenue: Total revenues for the fourth quarter of 2022 were $8,000 as compared with $27,000 for the fourth quarter of 2021. Total
  - Net income: Net loss attributable to AgeX for the year ended December 31, 2022 was $10.5 million
  - EPS: ($0.28) per share (basic and diluted)
  - Result: reported results
  source text: AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/0001493152-23-010315-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.